Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidance on JAK inhibitor treatment for inborn errors of JAK-STAT signaling (2026). An international consensus statement on behalf of the ESID/EBMT-IEWP and ERN-RITA.

The Journal of allergy and clinical immunology·2026
Same author

[Imported infectious diseases in tertiary hospital].

Anales de pediatria (Barcelona, Spain : 2003)·2013
Same author

[Fever and skin lesions in a patient with chronic granulomatous disease].

Anales de pediatria (Barcelona, Spain : 2003)·2013
Same author

[Evaluation of a program for assessing adherence to antiretroviral treatment].

Anales de pediatria (Barcelona, Spain : 2003)·2011
Same author

[Spectrum of primary immunodeficiencies in a tertiary hospital over a period of 10 years].

Anales de pediatria (Barcelona, Spain : 2003)·2010
Same author

[Macroamylasaemia in paediatrics].

Anales de pediatria (Barcelona, Spain : 2003)·2009

Related Experiment Video

Updated: Jan 13, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.0K

[Subcutaneous gammaglobulin in common variable immunodeficiency. First experience in Spain].

M Maroto Hernando1, P Soler Palacín, N Martin Nalda

  • 1Sección de Cardiología Infantil, Hospital Infantil La Fe, Valencia, España.

Anales De Pediatria (Barcelona, Spain : 2003)
|February 17, 2009
PubMed
Summary

Weekly home-based subcutaneous immunoglobulin (SCIg) therapy offers a safe and cost-effective alternative to intravenous immunoglobulin (IVIg) for primary antibody deficiencies. SCIg improves quality of life and maintains adequate IgG levels with manageable side effects.

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.2K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.9K

Related Experiment Videos

Last Updated: Jan 13, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.0K
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.2K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.9K

Area of Science:

  • Immunology
  • Pharmacology
  • Patient Care

Context:

  • Primary antibody deficiencies require immunoglobulin replacement therapy.
  • Subcutaneous immunoglobulin (SCIg) therapy is an emerging alternative to traditional intravenous immunoglobulin (IVIg).
  • Home-based administration offers potential benefits in patient convenience and cost.

Purpose:

  • To evaluate the efficacy, safety, quality of life, and cost-effectiveness of weekly home-based SCIg.
  • To compare SCIg outcomes with previous IVIg treatment in pediatric patients with common variable immunodeficiency (CVID).

Summary:

  • Eleven pediatric CVID patients switched to SCIg, maintaining or reducing dose compared to IVIg.
  • SCIg resulted in significantly higher median trough serum IgG levels (850 mg/dl vs. 622 mg/dl) without increasing infection rates (p = 0.212).
  • Treatment-related adverse events were mostly mild local reactions, decreasing over time; quality of life improved significantly, with substantial cost savings.

Impact:

  • SCIg is a safe, effective, and cost-effective alternative for primary antibody deficiency treatment.
  • Home-based SCIg significantly enhances patient quality of life.
  • This therapy provides higher serum IgG levels with manageable adverse events, supporting its clinical adoption.